These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 31885183)

  • 1. Identification of RNPC3 as a novel JAK2 fusion partner gene in B-acute lymphoblastic leukemia refractory to combination therapy including ruxolitinib.
    Chen X; Wang F; Zhang Y; Ma X; Liu M; Cao P; Zhou L; Wang L; Zhang X; Wang T; Liu H
    Mol Genet Genomic Med; 2020 Mar; 8(3):e1110. PubMed ID: 31885183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel JAK2 rearrangement resulting from a t(9;22)(p24;q11.2) in B-acute lymphoblastic leukemia.
    Tirado CA; Chen W; Huang LJ; Laborde C; Hiemenz MC; Valdez F; Ho K; Winick N; Lou Z; Koduru P
    Leuk Res; 2010 Dec; 34(12):1674-6. PubMed ID: 20594592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib/nilotinib cotreatment inhibits leukemia-propagating cells in Philadelphia chromosome-positive ALL.
    Kong Y; Wu YL; Song Y; Shi MM; Cao XN; Zhao HY; Qin YZ; Lai YY; Jiang H; Jiang Q; Huang XJ
    J Transl Med; 2017 Aug; 15(1):184. PubMed ID: 28854975
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathologic characteristics, genetic features, and treatment options for acute lymphoblastic leukemia with JAK2 rearrangement-A 10-case study and literature review.
    Zhang L; Shah B; Zhang Y; Tashkandi H; Xiao W; Fernandez-Pol S; Vergara-Lluri M; Hussaini M; Song J; Lancet J; Moscinski L; Yun S; Lu CM; Medeiros LJ; Tang G
    Hum Pathol; 2023 Jun; 136():1-15. PubMed ID: 36958463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic challenges and clinical course of a myeloid/lymphoid neoplasm with eosinophilia and
    Lee WY; Pfau RB; Choi SM; Yang J; Xiao H; Putnam EM; Ryan RJ; Bixby DL; Shao L
    Cold Spring Harb Mol Case Stud; 2020 Apr; 6(2):. PubMed ID: 32238402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel SSBP2-JAK2 fusion gene resulting from a t(5;9)(q14.1;p24.1) in pre-B acute lymphocytic leukemia.
    Poitras JL; Dal Cin P; Aster JC; Deangelo DJ; Morton CC
    Genes Chromosomes Cancer; 2008 Oct; 47(10):884-9. PubMed ID: 18618714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy of ruxolitinib and chemotherapy in a child with Philadelphia chromosome-like acute lymphoblastic leukemia with
    Ding YY; Stern JW; Jubelirer TF; Wertheim GB; Lin F; Chang F; Gu Z; Mullighan CG; Li Y; Harvey RC; Chen IM; Willman CL; Hunger SP; Li MM; Tasian SK
    Haematologica; 2018 Sep; 103(9):e427-e431. PubMed ID: 29773603
    [No Abstract]   [Full Text] [Related]  

  • 8. Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
    Mayfield JR; Czuchlewski DR; Gale JM; Matlawska-Wasowska K; Vasef MA; Nickl C; Pickett G; Ness SA; Winter SS
    Pediatr Blood Cancer; 2017 May; 64(5):. PubMed ID: 27860260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained remission after ruxolitinib and chimeric antigen receptor T-cell therapy bridged to a second allogeneic hematopoietic stem cell transplantation for relapsed Philadelphia chromosome-like B-cell precursor acute lymphoblastic leukemia with novel NPHP3-JAK2 fusion.
    Chen X; Yuan L; Zhou J; Wang F; Zhang Y; Ma X; Cao P; Fang J; Chen J; Zhou X; Wu Q; Liu M; Liu H
    Genes Chromosomes Cancer; 2022 Jan; 61(1):55-58. PubMed ID: 34418218
    [No Abstract]   [Full Text] [Related]  

  • 10. IGF2BP1: a novel IGH translocation partner in B acute lymphoblastic leukemia.
    Gu G; Sederberg MC; Drachenberg MR; South ST
    Cancer Genet; 2014; 207(7-8):332-4. PubMed ID: 25195122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase.
    Cuesta-Domínguez Á; Ortega M; Ormazábal C; Santos-Roncero M; Galán-Díez M; Steegmann JL; Figuera Á; Arranz E; Vizmanos JL; Bueren JA; Río P; Fernández-Ruiz E
    PLoS One; 2012; 7(2):e32451. PubMed ID: 22384256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition.
    Lazarevic V; Lilljebjörn H; Olsson-Arvidsson L; Orsmark-Pietras C; Ågerstam H
    Genes Chromosomes Cancer; 2024 Aug; 63(8):e23261. PubMed ID: 39105620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Occurrence of TEL-AML1 fusion resulting from (12;21) translocation in human early B-lineage leukemia cell lines.
    Uphoff CC; MacLeod RA; Denkmann SA; Golub TR; Borkhardt A; Janssen JW; Drexler HG
    Leukemia; 1997 Mar; 11(3):441-7. PubMed ID: 9067587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BCR-JAK2 fusion in a myeloproliferative neoplasm with associated eosinophilia.
    He R; Greipp PT; Rangan A; Mai M; Chen D; Reichard KK; Nelsen LL; Pardanani A; Hanson CA; Viswanatha DS
    Cancer Genet; 2016 May; 209(5):223-8. PubMed ID: 27134074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 is dispensable for maintenance of JAK2 mutant B-cell acute lymphoblastic leukemias.
    Kim SK; Knight DA; Jones LR; Vervoort S; Ng AP; Seymour JF; Bradner JE; Waibel M; Kats L; Johnstone RW
    Genes Dev; 2018 Jun; 32(11-12):849-864. PubMed ID: 29907650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of
    Zhang XY; Dai HP; Li Z; Yin J; Lang XP; Yang CX; Xiao S; Zhu MQ; Liu DD; Liu H; Shen HJ; Wu DP; Tang XW
    Front Oncol; 2020; 10():611467. PubMed ID: 33505919
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Numerical gain and structural rearrangements of JAK2, identified by FISH, characterize both JAK2617V>F-positive and -negative patients with Ph-negative MPD, myelodysplasia, and B-lymphoid neoplasms.
    Najfeld V; Cozza A; Berkofsy-Fessler W; Prchal J; Scalise A
    Exp Hematol; 2007 Nov; 35(11):1668-76. PubMed ID: 17976519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic stem cell transplantation for pediatric mature B-cell acute lymphoblastic leukemia with non-L3 morphology and MLL-AF9 gene fusion: three case reports and review of the literature.
    Sarashina T; Iwabuchi H; Miyagawa N; Sekimizu M; Yokosuka T; Fukuda K; Hamanoue S; Iwasaki F; Goto S; Shiomi M; Imai C; Goto H
    Int J Hematol; 2016 Jul; 104(1):139-43. PubMed ID: 27084248
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.